eravacycline and Pneumonia

eravacycline has been researched along with Pneumonia* in 1 studies

Other Studies

1 other study(ies) available for eravacycline and Pneumonia

Article	Year
Efficacy of Eravacycline The Annals of pharmacotherapy, 2022, Volume: 56, Issue:12 Multidrug-resistant. To assess the efficacy of eravacycline compared with best previously available therapy in adults with difficult-to-treat resistant (DTR). This was a retrospective study of adults hospitalized for pneumonia with DTR. Ninety-three patients were included, with 27 receiving eravacycline. Eravacycline was associated with higher 30-day mortality (33%. Eravacycline-based combination therapy had similar outcomes to best previously available combination therapy for adults with DTR Topics: Acinetobacter baumannii; Acinetobacter Infections; Adult; Anti-Bacterial Agents; Bacteremia; COVID-19; Drug Resistance, Multiple, Bacterial; Humans; Pneumonia; Retrospective Studies; SARS-CoV-2; Tetracyclines	2022

Article

Year

The Annals of pharmacotherapy, 2022, Volume: 56, Issue:12

Multidrug-resistant. To assess the efficacy of eravacycline compared with best previously available therapy in adults with difficult-to-treat resistant (DTR). This was a retrospective study of adults hospitalized for pneumonia with DTR. Ninety-three patients were included, with 27 receiving eravacycline. Eravacycline was associated with higher 30-day mortality (33%. Eravacycline-based combination therapy had similar outcomes to best previously available combination therapy for adults with DTR

Topics: Acinetobacter baumannii; Acinetobacter Infections; Adult; Anti-Bacterial Agents; Bacteremia; COVID-19; Drug Resistance, Multiple, Bacterial; Humans; Pneumonia; Retrospective Studies; SARS-CoV-2; Tetracyclines

2022